ASSET PURCHASE AND LICENSE AGREEMENT by and among AGRIGENETICS, INC., a Delaware corporation; MYCOGEN CORPORATION, a California corporation; EXELIXIS PLANT SCIENCES, INC., a Delaware corporation; AGRINOMICS, LLC, a Delaware limited liability company;...Asset Purchase and License Agreement • November 5th, 2007 • Exelixis Inc • Services-commercial physical & biological research • New York
Contract Type FiledNovember 5th, 2007 Company Industry Jurisdiction[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
CONTRACT RESEARCH AGREEMENTContract Research Agreement • November 5th, 2007 • Exelixis Inc • Services-commercial physical & biological research • New York
Contract Type FiledNovember 5th, 2007 Company Industry Jurisdiction[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
LEASE AGREEMENTLease Agreement • November 5th, 2007 • Exelixis Inc • Services-commercial physical & biological research
Contract Type FiledNovember 5th, 2007 Company IndustryTHIS LEASE AGREEMENT (this “Lease”) is made as of the 14th day of September, 2007, between ARE-SAN FRANCISCO NO. 12, LLC, a Delaware limited liability company (“Landlord”), and EXELIXIS, INC., a Delaware corporation (“Tenant”).
AMENDMENT NO. 1 TO THE COLLABORATION AGREEMENT BETWEEN EXELIXIS, INC., AND BRISTOL-MYERS SQUIBB COMPANYExelixis Inc • November 5th, 2007 • Services-commercial physical & biological research
Company FiledNovember 5th, 2007 IndustryTHIS AMENDMENT NO. 1 (“Amendment No. 1”) to the Agreement (defined below) is effective on January 11, 2007 (the “Amendment No. 1 Effective Date”) by and between Exelixis, Inc., a Delaware corporation located at 170 Harbor Way, P.O. Box 511, South San Francisco, California 94083-0511 (“Exelixis”) and Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Exelixis and BMS may be referred to individually as a “Party” and collectively as the “Parties”.